Inventor · disambiguated record
Claudio Mapelli
Also filed as: MAPELLI CLAUDIO
29 granted patents·14 pending applications·302 citations·filing 1992–2024
97Inventor score
Top patents by PatentIndex Score
43 records- 0196US9308236B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Apr 12, 2016·51 cites·5 claims
- 0293US9856292B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 2, 2018·12 cites·32 claims
- 0392US9850283B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 26, 2017·12 cites·1 claims
- 0491US10266578B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Apr 23, 2019·9 cites·30 claims
- 0591US7417028B2Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2005·Granted Aug 26, 2008·20 cites·22 claims
- 0690US10633419B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Apr 28, 2020·7 cites·4 claims
- 0790US9861680B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 9, 2018·10 cites·3 claims
- 0890US7238670B2Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted Jul 3, 2007·32 cites·27 claims
- 0989US9605024B2PAR4 agonist peptidesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 28, 2017·4 cites·16 claims
- 1087US11358988B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 14, 2022·2 cites·8 claims
- 1187US10450347B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Oct 22, 2019·6 cites·23 claims
- 1287US7238671B2Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jul 3, 2007·24 cites·19 claims
- 1386US7534763B2Sustained release GLP-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted May 19, 2009·5 cites·25 claims
- 1484US10538555B2Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 21, 2020·8 cites·3 claims
- 1583US5519115AReverse antimicrobial peptidesENICHEM SPA·Filed 1993·Granted May 21, 1996·50 cites·22 claims
- 1681US9303065B2PAR4 agonist peptidesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Apr 5, 2016·2 cites·4 claims
- 1781US8927688B2PAR4 agonist peptidesBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 6, 2015·2 cites·13 claims
- 1879US12097242B2Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·26 claims
- 1978US12097241B2Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 24, 2024·0 cites·17 claims
- 2078US11952434B2ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Apr 9, 2024·0 cites·6 claims
- 2177US7960349B2N-terminally modified GLP-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2007·Granted Jun 14, 2011·2 cites·18 claims
- 2275US11364281B2Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jun 21, 2022·0 cites·2 claims
- 2375US7314726B2Beta secretase exosite binding peptides and methods for identifying beta secretase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jan 1, 2008·6 cites·3 claims
- 2474US11185570B2Method of treating cardiovascular disease and heart failure with modified relaxin polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 30, 2021·0 cites·20 claims
- 2568US5424395AAntimicrobial peptides active against plant pathogensENICHEM SPA·Filed 1992·Granted Jun 13, 1995·22 cites·27 claims
- 2663US2025163104A1Macrocyclic immunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2763US2024287138A1Cyclic peptides for inhibiting tnf receptor 1 activityMERCK SHARP & DOHME LLC·Filed 2024·Application pending·0 cites
- 2862US2024360178A1Macrocyclic immunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 2961US2024409585A1Macrocyclic immunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 3058US2007287670A1Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 3157US9482665B2Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standardsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 1, 2016·0 cites·4 claims
- 3257US2017369530A1Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactionsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 3356US5516642APolypeptides derived from major histocompatibility complex Class I antigenBRISTOL MYERS SQUIBB CO·Filed 1992·Granted May 14, 1996·16 cites·13 claims
- 3456US2008242593A1Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2008·Application pending·0 cites
- 3552US10670612B2Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standardsSALADAX BIOMEDICAL INC·Filed 2016·Granted Jun 2, 2020·0 cites·4 claims
- 3651US2010022457A1Sustained release glp-1 receptor modulatorsBRISTOL MYERS SQUIBB CO·Filed 2006·Application pending·0 cites
- 3748US2010210552A1Human glucagon-like peptide-1 mimics and their use in the treatment of diabetes and related conditionsBRISTOL MYERS SQUIBB CO·Filed 2010·Application pending·0 cites
- 3845US10823739B2Immunoassay standards and measurement of tau using intra-assay calibration standardsSALADAX BIOMEDICAL·Filed 2013·Granted Nov 3, 2020·0 cites·9 claims
- 3945US2007238669A1Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditionsBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 4044US2012309028A1Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standardsRHYNE PAUL·Filed 2011·Application pending·0 cites
- 4144US2016222060A1ImmunomodulatorsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 4242US2007149763A1Beta secretase exosite binding peptides and methods for identifying beta secretase modulatorsBRISTOL MYERS SQUIBB CO·Filed 2007·Application pending·0 cites
- 4341US2007021346A1N-terminally modified GLP-1 receptor modulatorsEWING WILLIAM R·Filed 2006·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →